De-Differentiation Confers Multidrug Resistance Via Noncanonical PERK-Nrf2 Signaling

PLoS Biology

Volumn 12, Issue 9, 2014, Pages

  Del Vecchio, Catherine A ^a   Feng, Yuxiong ^a   Sokol, Ethan S ^b   Tillman, Erik J ^b   Sanduja, Sandhya ^a   Reinhardt, Ferenc ^a   Gupta, Piyush B ^a,b,c,d,e  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH   (United States)

^d HARVARD STEM CELL INSTITUTE   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; DOXORUBICIN; HEME OXYGENASE 1; INITIATION FACTOR 2ALPHA; MENADIONE; OLTIPRAZ; PACLITAXEL; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR TWIST; ANTINEOPLASTIC AGENT; EIF2AK3 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PROTEIN KINASE R;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CANCER GRADING; CANCER RESISTANCE; CANCER SURVIVAL; CELL DEDIFFERENTIATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DRUG SENSITIZATION; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; HMOX 1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PERK GENE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BREAST NEOPLASMS; CARCINOMA; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSCRIPTION; GENETICS; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; NEOPLASM RECURRENCE, LOCAL; NONOBESE DIABETIC MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE; UDDER;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CELL DEDIFFERENTIATION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EIF-2 KINASE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED NOD; MICE, SCID; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84920464700     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001945     Document Type: Article

References (69)

1. Gottesman MM, (1993) How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53: 747–754.
2. Simon SM, Schindler M, (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A 91: 3497–3504.
3. Choi CH, (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5: 30.
4. Lobo NA, Shimono Y, Qian D, Clarke MF, (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23: 675–699.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105–111.
6. Stingl J, Caldas C, (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7: 791–799.
7. Thiery JP, (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442–454.
8. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704–715.
9. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3: e2888.
10. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, et al. (2007) The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26: 6979–6988.
11. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, et al. (2012) Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/beta-catenin signaling. Stem Cells 30: 2366–2377.
12. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, et al. (2013) SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2: e61.
13. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, et al. (2011) Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145: 926–940.
14. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, et al. (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152: 25–38.
15. Saxena M, Stephens MA, Pathak H, Rangarajan A, (2011) Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2: e179.
16. Singh A, Settleman J, (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741–4751.
17. Gammon L, Biddle A, Heywood HK, Johannessen AC, Mackenzie IC, (2013) Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism. PLoS ONE 8: e62493.
18. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780–783.
19. Dean M, Fojo T, Bates S, (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275–284.
20. Azzi S, Bruno S, Giron-Michel J, Clay D, Devocelle A, et al. (2011) Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst 103: 1884–1898.
21. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, et al. (2010) Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 16: 2715–2728.
22. Grimwade D, Mistry AR, Solomon E, Guidez F, (2010) Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat Res 145: 219–235.
23. Ohno R, Asou N, Ohnishi K, (2003) Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 17: 1454–1463.
24. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, et al. (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15: 50–65.
25. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927–939.
26. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, et al. (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820–5828.
27. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, et al. (2009) Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15: 2657–2665.
28. Loor G, Kondapalli J, Schriewer JM, Chandel NS, Vanden Hoek TL, et al. (2010) Menadione triggers cell death through ROS-dependent mechanisms involving PARP activation without requiring apoptosis. Free Radic Biol Med 49: 1925–1936.
29. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, et al. (1999) Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 274: 26071–26078.
30. Alam J, Wicks C, Stewart D, Gong P, Touchard C, et al. (2000) Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor. J Biol Chem 275: 27694–27702.
31. Maines MD, (1988) Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 2: 2557–2568.
32. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313–322.
33. Osburn WO, Kensler TW, (2008) Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 659: 31–39.
34. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, et al. (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29: 1235–1243.
35. McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, et al. (2001) The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 61: 3299–3307.
36. Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, et al. (2010) Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38: 5718–5734.
37. Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, et al. (2013) Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 51: 618–631.
38. Huang HC, Nguyen T, Pickett CB, (2002) Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 277: 42769–42774.
39. Lee JM, Hanson JM, Chu WA, Johnson JA, (2001) Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J Biol Chem 276: 20011–20016.
40. Shi Y, Vattem KM, Sood R, An J, Liang J, et al. (1998) Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Molecular and cellular biology 18: 7499–7509.
41. Harding HP, Zhang Y, Ron D, (1999) Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397: 271–274.
42. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, et al. (2003) Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Molecular and cellular biology 23: 7198–7209.
43. Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, et al. (2014) Epithelial-to-Mesenchymal Transition Activates PERK-eIF2alpha and Sensitizes Cells to Endoplasmic Reticulum Stress. Cancer Discov
44. Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, et al. (2012) Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). Journal of medicinal chemistry 55: 7193–7207.
45. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, et al. (2008) Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 25: 629–642.
46. Zafarullah M, Li WQ, Sylvester J, Ahmad M, (2003) Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60: 6–20.
47. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 98: 3410–3415.
48. Blais JD, Addison CL, Edge R, Falls T, Zhao H, et al. (2006) Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol 26: 9517–9532.
49. Wang Y, Alam GN, Ning Y, Visioli F, Dong Z, et al. (2012) The unfolded protein response induces the angiogenic switch in human tumor cells through the PERK/ATF4 pathway. Cancer Res 72: 5396–5406.
50. Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, et al. (2013) Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 73: 1993–2002.
51. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, et al. (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273–2284.
52. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, et al. (2010) Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220: 446–451.
53. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, et al. (2008) Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135: 1358–1354, 1358-1368, 1368, e1351-1354.
54. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, et al. (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420.
55. Mann MJ, Hendershot LM, (2006) UPR activation alters chemosensitivity of tumor cells. Cancer Biol Ther 5: 736–740.
56. Chatterjee S, Hirota H, Belfi CA, Berger SJ, Berger NA, (1997) Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78. Cancer Res 57: 5112–5116.
57. Jiang CC, Mao ZG, Avery-Kiejda KA, Wade M, Hersey P, et al. (2009) Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis 30: 197–204.
58. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, et al. (2003) Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 278: 20915–20924.
59. Gray MD, Mann M, Nitiss JL, Hendershot LM, (2005) Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs. Mol Pharmacol 68: 1699–1707.
60. Mandic A, Hansson J, Linder S, Shoshan MC, (2003) Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278: 9100–9106.
61. Ledoux S, Yang R, Friedlander G, Laouari D, (2003) Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 63: 7284–7290.
62. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, et al. (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90–97.
63. Boller YC, Brandes LM, Russell RL, Lin ZP, Patierno SR, et al. (2000) Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors. Oncol Res 12: 383–395.
64. Brandes LM, Lin ZP, Patierno SR, Kennedy KA, (2001) Reversal of physiological stress-induced resistance to topoisomerase II inhibitors using an inducible phosphorylation site-deficient mutant of I kappa B alpha. Mol Pharmacol 60: 559–567.
65. Hughes CS, Shen JW, Subjeck JR, (1989) Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res 49: 4452–4454.
66. Mann MJ, Pereira ER, Liao N, Hendershot LM, (2012) UPR-induced resistance to etoposide is downstream of PERK and independent of changes in topoisomerase IIalpha levels. PLoS ONE 7: e47931.
67. Shen J, Hughes C, Chao C, Cai J, Bartels C, et al. (1987) Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci U S A 84: 3278–3282.
68. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, et al. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146: 633–644.
69. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.